大中國區摘要
Region China Abstract

● 諾和諾德在整體胰島素市場的銷量市場份額達到48.5%。胰島素集中帶量采購已于2022年5月實施，受其影響，大中國區胰島素銷售額以丹麥克朗計算下降16%。同時，由諾和佳^?和諾和益^?帶來的增長，部分抵消了相關影響。

● Novo Nordisk has a volume market share of 48.5% of the total insulin market. Sales of insulin in Region China decreased by 16% measured in Danish kroner due to the implementation of Volume Based Procurement from May 2022. Meanwhile, the sales decline was partially countered by Ryzodeg^? and Xulthopy^?.

● 大中國區2型糖尿病治療領域GLP-1產品銷售以丹麥克朗計算增長102%，反映出諾和泰^?的強勁增長。諾和泰^?已被納入國家醫保目錄報銷體系。新版國家醫保藥品目錄已于2022年1月1日起正式實施。

● GLP-1 sales in Region China increased by 102% measured in Danish kroner. The sales growth reflects the uptake of Ozempic^?. Ozempic^? has been included on the National Reimbursement List in China. The new version of the National Reimbursement List in China has been implemented as of 1 January 2022.

● 大中國區罕見病領域銷售增長101%。

● Rare disease sales in Region China increased by 101%.

財報摘要
Financial Report Abstract

● 經營利潤以丹麥克朗計算增長28%，以固定匯率（CER）計算增長15%，至748億丹麥克朗。

● Operating profit increased by 28% in Danish kroner and by 15% at constant exchange rates (CER) to DKK 74.8 billion. 

● 北美運營部銷售以丹麥克朗計算增長35%（以CER計算增長21%），國際運營部銷售以丹麥克朗計算增長17%（以CER計算增長13%）。

● Sales in North America Operations increased by 35% in Danish kroner (21% at CER), and sales in International Operations increased by 17% in Danish kroner (13% at CER).

● 糖尿病和肥胖癥治療領域銷售以丹麥克朗計算增長29%，至1564億丹麥克朗（以CER計算增長19%），主要由GLP-1糖尿病治療領域銷售驅動，其以丹麥克朗計算增長56%（以CER計算增長42%）。罕見病領域銷售以丹麥克朗計算增長7%（以CER計算增長1%）。

● Sales within Diabetes and Obesity care increased by 29% in Danish kroner to DKK 156.4 billion (19% at CER), mainly driven by GLP-1 diabetes sales growth of 56% in Danish kroner (42% at CER). Rare disease sales increased by 7% measured in Danish kroner (1% at CER).

● 肥胖癥治療領域銷售以丹麥克朗計算增長101%（以CER計算增長84%）。2022年12月，Wegovy^?在美國市場的供貨已再次獲得保證。

● Obesity care sales grew by 101% in Danish Kroner (84% at CER). All Wegovy^? dose strengths were made available again in the US in December 2022.

● 在研發領域，諾和諾德在NASH領域啟動了兩項基于siRNA技術平臺的1期臨床試驗。

● Within R&D, Novo Nordisk initiated two phase 1 trials in NASH based on the siRNA technology platform.

● 展望2023年，以 CER 計算的銷售和經營利潤增長目前均預計為13-19%。以丹麥克朗報告的銷售和經營利潤增長目前預計將比以 CER 計算的增長率低分別4個和5個百分點。

● For the 2023 outlook, both sales and operating profit growth are expected to be 13-19% at CER. Sales and operating profit growth reported in Danish kroner are expected to be 4 and 5 percentage points lower than at CER, respectively. 

● 在將于2023年3月23日舉行的年度股東大會上，董事會將提議在2022年期末每股派息8.15丹麥克朗。預計2022年的總股息將為每股12.40丹麥克朗，其中每股4.25丹麥克朗的股息已于2022年8月作為中期股息予以派發。董事會還決定啟動一項為期12個月，最多280億丹麥克朗的新股票回購計劃。

● At the Annual General Meeting on 23 March 2023, the Board of Directors will propose a final dividend of DKK 8.15 for 2022 per share. The expected total dividend for 2022 is DKK 12.40 per share, of which DKK 4.25 was paid as interim dividend in August 2022. The Board of Directors has decided to initiate a new 12-month share repurchase programme of up to DKK 28 billion.

諾和諾德全球總裁兼CEO周賦德（Lars Fruergaard J?rgensen）表示：“我們對2022年實現雙位數銷售增長感到非常滿意。增長由用于糖尿病和肥胖癥治療的創新GLP-1類藥物所驅動。超過3600萬糖尿病患者從我們的治療產品中獲益。我們的戰略愿景持續取得進展，在2023年，我們將繼續專注于強大的業務運營，擴充并推進公司創新產品管線，并為擴大現有和未來的產品組合的產能進行重點投資。”

Lars Fruergaard J?rgensen, president and CEO: "We are very pleased with the double-digit sales growth in 2022 driven by our innovative GLP-1-based diabetes and obesity treatments, and more than 36 million people living with diabetes are now benefiting from our treatments. We continued to make progress on our Strategic aspirations and in 2023, we will continue our focus on strong commercial execution, expanding and progressing our innovative pipeline and investing significantly in the expansion of production capacity for current and future portfolio."